8 results about "Gene activity" patented technology

The invention discloses an inflammatory bowel disease treatment method based on intestinal flora regulatory gene CD24 expression. According to the method, expression or functions of CD24 in host intestinal epithelial cells are up-regulated, the intestinal flora structure is adjusted, and intestinal inflammation is relieved. CD24 up-regulation can be realized by transfecting a CD24 gene overexpression vector, applying a transcription factor or a small molecule agonist or enhancing the activity of an endogenous gene by utilizing a gene editing technology. The CD24 is regulated and controlled, so that the proportion of the phylum firmicalis to the phylum bacteroides can be normalized, the enrichment of short-chain fatty acid producing flora is promoted, the activation of NF-kappa B and NLRP3 inflammasomes is inhibited, and the intestinal barrier function is enhanced. The DSS induced colitis model is established by drinking a 2-5% dextran sodium sulfate solution by a mouse, and simulates the pathological characteristics of human ulcerative colitis. Intervention modes include oral administration, enema or nanoparticle targeted delivery of the CD24 agonist pharmaceutical composition. The invention provides a new strategy for the treatment of inflammatory bowel diseases, especially ulcerative colitis, and has obvious dual curative effects of anti-inflammation and flora regulation.

The method as disclosed herein utilizes a high throughput screening assay (GigaAssay) to produce a comprehensive mutation effect on gene activity (MEGA)-mutation activity profile (Map). The methods as disclosed herein can be used to assess the mutational effect for any gene, under any condition (e.g., drug treatment) with any assay in mammalian cells in culture. Thus, the methods provided herein can be utilized to discover and screen dominant negative variants, and provide a reliable solution to the problem of identifying unique pharmacologically active variants of proteins. Furthermore, the method provided herein can be integrated to cell-based assays to investigate disease pathology and test potential drugs.

The present invention provides a double-stranded RNA used to suppress the expression of mannan-binding lectin-related serine protease 2 (MASP2) in cells, cells containing the nucleotide encoding the same, and a method for treating a disease or condition mediated by or related to MASP2 expression in a subject using the dsRNA or cells.

The invention discloses a pig SINE-RIP probe combination, a gene chip, a kit and application, the pig SINE-RIP probe combination is based on a reference genome Sscrofa11.1, has wide variety and group applicability, and detects a type of SINE-RIP structure variation markers of SINE-RIP which is large in fragment, easy to cause gene activity change and large in genetic effect. The method is suitable for various applications and researches such as pig genome selective breeding, pig germplasm resource identification and evaluation, genetic relationship analysis, genetic diversity analysis and evaluation, functional gene or locus positioning, whole genome association analysis and the like, the detection process is convenient to operate, the flux is high, the cost is low, the detection rate is high, and the typing result is accurate. The probe combination effectively supplements and even substitutes an existing SNP molecular marker system, the accuracy of genome selection can be further improved, a brand-new high-reliability tool is provided for whole genome related research and application of pigs, and the industrial application value is extremely high.

The invention discloses a method for increasing glutamic acid yield. Modified bacteria that produce L-glutamic acid are provided wherein a heterologous polynucleotide of phosphoketolase (XFP), and one or more of a modification of increased activity of the gluAA1T, icd gene, aceE gene and / or pyc gene, are included in the genome as compared to non-modified bacteria. In addition, methods of increasing the yield of L-glutamic acid using the modified bacteria are also provided.

The invention discloses a test method of reaction of EPHX1 genotype based COPD to NAC. The test method comprises the following steps: extracting a DNA by a phenol / chloroform method and sequencing, dividing COPD patients into slow and very slow gene activity group and a quick and normal gene activity group according to EPHX1 gene polymorphism, giving 600 mg Bid of NAC for 1 year to both groups, performing baseline measurement of pulmonary function parameters, completing SGRQ and 6MWT, measuring FVC and FEV1 at a follow-up day every 12 weeks, completingSGRQ and 6MWT in 24 and 48 weeks, and recording the number of acute exacerbationof COPD in one year. The data were statistically analyzed with SPSS. The results show that NAC is effective in the treatment of slow and very slow EPHX1 gene activityCOPD patients. The test method provided by the invention provides a solid basis for demonstrating the effect and mechanism of NAC based on pharmacogenomics in the individualized treatment of COPD.

The present invention relates to a novel in vivo expression system for biocontainment and gene expression control in microbes including modified and / or unmodified for application in processes of altering cell multiplication, activating cell lysis, altering metabolism and product formation, etc. The said gene expression control system can be switched on (activated) and off (deactivated) depending on presence and absence of externally and / or internally active inducer or product of gene activity, etc. The said biocontainment and gene expression control system are useful for in vitro applications (production in Bioreactors) and also for in situ applications including but not limited to application on plant, soil, water treatment, aquaculture, cattle feed, gut applications, etc.

This invention discloses a KDM4C inhibitor and its applications, relating to the field of biomedical technology. Specifically, this invention discloses the application of the KDM4C inhibitor in any of A1) to A5): A1) preparing a drug for the prevention or treatment of obesity; A2) preparing a drug for reducing weight; A3) preparing a drug for reducing food intake; A4) preparing a drug for reducing insulin sensitivity; A5) preparing a drug for enhancing glucose homeostasis. This is achieved through knockout... Kdm4c Inhibiting KDM4C gene activity or inhibiting KDM4C activity can significantly reduce obesity induced by a high-fat diet, thereby regulating the secretion of related hormones / adipokines, affecting food intake, improving insulin resistance, and enhancing insulin sensitivity, making it a potential target for the treatment of obesity.